Pfizer Triumphs in Bidding War for Metsera Amidst Weight-Loss Drug Market Shakeup
Metsera shares fell 15% after Pfizer clinched a $10 billion deal, ending a bidding war with Novo Nordisk. The decision was influenced by antitrust concerns with Novo's bid. Pfizer's acquisition grants them access to the obesity drug market, despite Metsera's drugs being in early development.
In a dramatic turn of events, shares of Metsera plummeted over 15% on Monday following the company's acceptance of a $10 billion buyout offer from U.S. drugmaker Pfizer. This decision effectively concluded a heated bidding contest with Danish pharmaceutical counterpart Novo Nordisk.
Metsera cited potential U.S. antitrust issues with Novo Nordisk's previously superior bid as a pivotal factor in their decision to align with Pfizer. Following this development, Novo announced its withdrawal from the acquisition race over the weekend.
Pfizer's victory in acquiring Metsera paves its way into the burgeoning obesity drug sector. However, concerns loom as Metsera's products are still in development stages and U.S. drugmakers face pressures to reduce prescription drug costs.
(With inputs from agencies.)
- READ MORE ON:
- Pfizer
- Metsera
- Novo Nordisk
- obesity
- weight-loss
- drug market
- acquisition
- bidding war
- antitrust
- biotech
ALSO READ
US Air Force Accelerates New Fleet with 747-8 Acquisition
Major Stake Acquisition: Tata AIA and Aranda Investments Secure 1.4% in SBFC Finance
CCI Clears ITC's Strategic Acquisition of Aditya Birla's Pulp and Paper Business
RBI Greenlights HDFC's 9.5% Stake Acquisition in IndusInd Bank
FDA's Accelerated Review: Balancing Speed and Safety in Weight-Loss Pill Approval

